Beranda › Neoplasma Mieloproliferatif › Wisconsin › Madison
Uji klinis Neoplasma Mieloproliferatif di Madison, WI
3 studi untuk Neoplasma Mieloproliferatif mencari peserta di lokasi sekitar Madison (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Uji klinis Neoplasma Mieloproliferatif di kota lain
- Houston, TX16 studi
- New York City, NY15 studi
- Boston, MA14 studi
- Milwaukee, WI10 studi
- Miami, FL10 studi
- Chicago, IL9 studi
- Durham, NC9 studi
- Baldwin Park, CA9 studi
- Seattle, WA9 studi
- Atlanta, GA8 studi
- Tampa, FL8 studi
- Birmingham, AL8 studi
Studi lain di Madison
- Kanker Prostat29 studi
- Kanker Kolorektal22 studi
- Kanker Payudara22 studi
- Kanker Metastatik21 studi
- Kanker Paru Non-Sel Kecil16 studi
- Leukemia Mieloid Akut16 studi
- Melanoma15 studi
- Kanker (semua jenis)14 studi
- Kanker Ovarium13 studi
- Kanker Lambung11 studi
- Kanker Paru10 studi
- Kanker Pankreas10 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.